Cleveland Clinic Pulmonary Hypertension Summit 2022

Pulmonary Hypertension Summit will provide you with an overview of the practical issues in the diagnosis, evaluation, and management of patients with pulmonary hypertension. Expert speakers will present the most recent advances in the context of challenges faced by physicians and other health care providers caring for these patients. Faculty will present on advances in diagnosis and risk stratification, emerging therapeutics, management of populations with concomitant disease, and technological innovations. Take advantage of this unique opportunity, either in-person or via live stream.

LEARNING OBJECTIVES

By attending, you will be able to:

• Discuss the diagnostic strategies for pulmonary arterial hypertension, including recommendations for hemodynamic evaluation, diagnosis, clinical classification, and risk stratification.
• Detail the advantages and limitation of risk assessment tools for PH and describe their role in treatment decisions.
• Critically review pharmacologic therapies for pulmonary hypertension, their efficacy and side effect data, and indications for clinical practice.
• Describe associated conditions that occur in patients with PH, including heart failure, interstitial lung disease, thromboembolic PH, and potentially COVID-19, and review their diagnosis and management.
• Summarize research advances in molecular, cellular, and clinical areas and discuss their clinical implications.

TARGET AUDIENCE

This summit is directed to physicians, pharmacists, and nurses with an interest in pulmonary hypertension.

+ Topics:

• Course Syllabus.pdf
• Session I PAH Present and Future Advances in the Diagnostic and Hemodynamic Evaluation of PH.mp4
• Session I PAH Present and Future Emerging Therapeutics for PAH.mp4
• Session I PAH Present and Future Risk Stratification and Current Treatment Algorithm.mp4
• Session II PH Special Populations Chronic Thromboembolic PH.mp4
• Session II PH Special Populations PH in HFpEF What can we do.mp4
• Session II PH Special Populations PH in ILD Finally some hope.mp4
• Session II PH Special Populations Pulmonary Vascular Limitation After COVID- What is known so far.mp4
• Session III PH Cutting Edge Heterogeneity of Metabolic Endo-Phenotypes of PAH.mp4
• Session III PH Cutting Edge Metabolic Interventions in PAH.mp4
• Session III PH Cutting Edge PAH Single Cell Omics Atlas.mp4
• Session III PH Cutting Edge PVDOMICs.mp4